Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Denileukin Diftitox Plus Pegylated IFNα-2a in Advanced Ovarian Cancer
NCT01773889Phase 2Terminated
- Sponsor
- UT Health San Antonio
- Start
- Jun 2009
- Primary completion
- Jun 2011
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 2 trial of denileukin diftitox, peginterferon alfa-2a in ovarian cancer, fallopian tube cancer (PFTC), primary peritoneal cancer (PPC), sponsored by UT Health San Antonio. Started Jun 2009; status: terminated.
02
Drugs
denileukin diftitoxpeginterferon alfa-2a
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT01773889.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01773889.